Targeted next-generation sequencing of candidate genes reveals novel mutations in patients with dilated cardiomyopathy

International Journal of Molecular Medicine

Volumn 36, Issue 6, 2015, Pages 1479-1486

  Zhao, Yue ^a   Feng, Yue ^a   Zhang, Yun Mei ^b   Ding, Xiao Xue ^b   Song, Yu Zhu ^a   Zhang, A Mei ^a   Liu, Li ^a   Zhang, Hong ^b   Ding, Jia Huan ^a   Xia, Xue Shan ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b First People's Hospital of Yunnan Province   (China)

Author keywords

Candidate genes; Dilated cardiomyopathy; Genetic testing; Next generation sequencing

Indexed keywords

ACTIN ALPHA CARDIAC MUSCLE 1; ALPHA TROPOMYOSIN; CARDIAC MYOSIN BINDING PROTEIN C; CYTOSKELETON PROTEIN; DESMIN; DESMOPLAKIN; MYOPALLADIN; MYOSIN HEAVY CHAIN ALPHA 6; MYOSIN HEAVY CHAIN BETA 7; MYOSIN LIGHT CHAIN 3; RNA BINDING MOTIF PROTEIN 20; SODIUM CHANNEL NAV1.5; TROPONIN I TYPE 3; TROPONIN T TYPE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOSKELETON; FEMALE; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INDEL MUTATION; MALE; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SARCOMERE; ANALYSIS OF VARIANCE; CARDIOMYOPATHY, DILATED; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANALYSIS OF VARIANCE; CARDIOMYOPATHY, DILATED; ELECTROCARDIOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84945394385     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2361     Document Type: Article

References (46)

1. Taylor MR, Carniel E, and Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis. 1: 27, 2006.
2. Hershberger RE, and Siegfried JD. Update. 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 57: 1641-1649, 2011.
3. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, Burnett JC, Rodeheffer RJ, Chesebro JH, and Tazelaar HD. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 326: 77-82, 1992.
4. Hershberger RE, Hedges DJ, and Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 10: 531-547, 2013.
5. Zhao L, Xu JH, Xu WJ, Yu H, Wang Q, Zheng HZ, Jiang WF, Jiang JF, and Yang YQ. A novel GATA4 loss-of-function mutation responsible for familial dilated cardiomyopathy. Int J Mol Med. 33: 654-660, 2014.
6. Zhou W, Zhao L, Jiang JQ, Jiang WF, Yang YQ, and Qiu XB. A novel TBX5 loss-of-function mutation associated with sporadic dilated cardiomyopathy. Int J Mol Med. 36: 282-288, 2015.
7. Xu L, Zhao L, Yuan F, Jiang WF, Liu H, Li RG, Xu YJ, Zhang M, Fang WY, Qu XK, et al. GATA6 loss-of-function mutations contribute to familial dilated cardiomyopathy. Int J Mol Med. 34: 1315-1322, 2014.
8. Zhang XL, Dai N, Tang K, Chen YQ, Chen W, Wang J, Zhao CM, Yuan F, Qiu XB, Qu XK, et al. GATA5 loss-of-function mutation in familial dilated cardiomyopathy. Int J Mol Med. 35: 763-770, 2015.
9. Yuan F, Qiu XB, Li RG, Qu XK, Wang J, Xu YJ, Liu X, Fang WY, Yang YQ, and Liao DN. A novel NKX2-5 loss-of-function mutation predisposes to familial dilated cardiomyopathy and arrhythmias. Int J Mol Med. 35: 478-486, 2015.
10. Hershberger RE, Morales A, and Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med. 12: 655-667, 2010.
11. Murphy RT, Mogensen J, Shaw A, Kubo T, Hughes S, and McKenna WJ. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet. 363: 371-372, 2004.
12. Roh JI, Cheong C, Sung YH, Lee J, Oh J, Lee BS, Lee JE, Gho YS, Kim DK, Park CB, et al. Perturbation of NCOA6 leads to dilated cardiomyopathy. Cell Rep. 8: 991-998, 2014.
13. Man E, Lafferty KA, Funke BH, Lun KS, Chan SY, Chau AK, and Chung BH. NGS identifies TAZ mutation in a family with X-linked dilated cardiomyopathy. BMJ Case Rep. 2013: pii: bcr2012007529, 2013.
14. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, Helio T, Keren A, McKenna WJ, Monserrat L, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases: Genetic counselling and testing in cardio-myopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 31 2715-2726 2010.
15. Posafalvi A, Herkert JC, Sinke RJ, van den Berg MP, Mogensen J, Jongbloed JD, and van Tintelen JP. Clinical utility gene card for: dilated cardiomyopathy (CMD). Eur J Hum Genet. 21: 21, 2013.
16. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 9: 387-402, 2008.
17. Schuster SC. Next-generation sequencing transforms today's biology. Nat Methods. 5: 16-18, 2008.
18. Ware SM. Genetic diagnosis in pediatric cardiomyopathy: clinical application and research perspectives. Prog Pediatr Cardiol. 31: 99-102, 2011.
19. Biswas A, Rao VR, Seth S, and Maulik SK. Next generation sequencing in cardiomyopathy: towards personalized genomics and medicine. Mol Biol Rep. 41: 4881-4888, 2014.
20. Punetha J, and Hoffman EP. Short read (next-generation) sequencing: a tutorial with cardiomyopathy diagnostics as an exemplar. Circ Cardiovasc Genet. 6: 427-434, 2013.
21. Mestroni L, Maisch B, McKenna WJ, Schwartz K, Charron P, Rocco C, Tesson F, Richter A, Wilke A, and Komajda M. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 20: 93-102, 1999.
22. Li H, and Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 26: 589-595, 2010.
23. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, and Durbin R; 1000 Genome Project Data Processing Subgroup: The Sequence Alignment/Map format and SAMtools. Bioinformatics 25 2078-2079 2009.
24. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, and Wilson RK. VarScan. 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22: 568-576, 2012.
25. Wang K, Li M, and Hakonarson H. ANNOVAR: functional anno-Tation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res. 38: e164, 2010.
26. Tester DJ, and Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelo-pathies in clinical practice. Circulation. 123: 1021-1037, 2011.
27. Maron BJ, and Semsarian C. Prevention of sudden death for patients with cardiomyopathies another step forward. J Am Coll Cardiol. 59: 501-502, 2012.
28. Chiu C, Tebo M, Ingles J, Yeates L, Arthur JW, Lind JM, and Semsarian C. Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 43: 337-343, 2007.
29. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, and Ward BE; Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee: ACMG recommen-dations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 10 294-300 2008.
30. Kumar P, Henikoff S, and Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 4: 1073-1081, 2009.
31. Schwarz JM, Rödelsperger C, Schuelke M, and Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 7: 575-576, 2010.
32. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, and Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 7: 248-249, 2010.
33. Wang S, Zou Y, Fu C, Xu X, Wang J, Song L, Wang H, Chen J, Wang J, Huan T, and Hui R. Worse prognosis with gene mutations of beta-myosin heavy chain than myosin-binding protein C in Chinese patients with hypertrophic cardiomyopathy. Clin Cardiol. 31: 114-118, 2008.
34. Robinson P, Griffiths PJ, Watkins H, and Redwood CS. Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-Tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res. 101: 1266-1273, 2007.
35. Mirza M, Marston S, Willott R, Ashley C, Mogensen J, McKenna W, Robinson P, Redwood C, and Watkins H. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J Biol Chem. 280: 28498-28506, 2005.
36. Mller DV, Andersen PS, Hedley P, Ersbll MK, Bundgaard H, Moolman-Smook J, Christiansen M, and Kber L. The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy. Eur J Hum Genet. 17: 1241-1249, 2009.
37. Hershberger RE, Norton N, Morales A, Li D, Siegfried JD, and Gonzalez-Quintana J. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet. 3: 155-161, 2010.
38. Hershberger RE, Parks SB, Kushner JD, Li D, Ludwigsen S, Jakobs P, Nauman D, Burgess D, Partain J, and Litt M. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci. 1: 21-26, 2008.
39. Lakdawala NK, Funke BH, Baxter S, Cirino AL, Roberts AE, Judge DP, Johnson N, Mendelsohn NJ, Morel C, Care M, et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail. 18: 296-303, 2012.
40. Liu W, Liu W, Hu D, Zhu T, Ma Z, Yang J, Xie W, Li C, Li L, Yang J, et al. Mutation spectrum in a large cohort of unrelated Chinese patients with hypertrophic cardiomyopathy. Am J Cardiol. 112: 585-589, 2013.
41. Matsushita Y, Furukawa T, Kasanuki H, Nishibatake M, Kurihara Y, Ikeda A, Kamatani N, Takeshima H, and Matsuoka R. Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy. J Hum Genet. 52: 543-548, 2007.
42. Zou Y, Wang J, Liu X, Wang Y, Chen Y, Sun K, Gao S, Zhang C, Wang Z, Zhang Y, et al. Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy. Mol Biol Rep. 40: 3969-3976, 2013.
43. Wang J, Xu SJ, Zhou H, Wang LJ, Hu B, Fang F, Zhang XM, Luo YW, He XY, Zhuang SW, et al. A novel mutation of the beta myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. Clin Cardiol. 32: E16-E21, 2009.
44. Carniel E, Taylor MR, Sinagra G, Di Lenarda A, Ku L, Fain PR, Boucek MM, Cavanaugh J, Miocic S, Slavov D, et al. Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation. 112: 54-59, 2005.
45. Herman DS, Hovingh GK, Iartchouk O, Rehm HL, Kucherlapati R, Seidman JG, and Seidman CE. Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods. 6: 507-510, 2009.
46. Sikkema-Raddatz B, Johansson LF, de Boer EN, Almomani R, Boven LG, van den Berg MP, van Spaendonck-Zwarts KY, van Tintelen JP, Sijmons RH, Jongbloed JD, and Sinke RJ. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat. 34: 1035-1042, 2013.